263 related articles for article (PubMed ID: 30881522)
1. Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis.
Yao L; Liu M; Huang Y; Wu K; Huang X; Zhao Y; He W; Zhang R
Dis Markers; 2019; 2019():6230162. PubMed ID: 30881522
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Nie SP; Chen H; Zhuang MQ; Lu M
Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538
[TBL] [Abstract][Full Text] [Related]
3. Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.
Mekuria AN; Ayele Y; Tola A; Mishore KM
J Diabetes Res; 2019; 2019():7676909. PubMed ID: 31828167
[TBL] [Abstract][Full Text] [Related]
4. The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta-analysis.
Xiao K; Liu F; Liu J; Xu J; Wu Q; Li X
J Clin Pharm Ther; 2020 Aug; 45(4):783-792. PubMed ID: 32406122
[TBL] [Abstract][Full Text] [Related]
5. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
6. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Wang Z; Lai ST; Xie L; Zhao JD; Ma NY; Zhu J; Ren ZG; Jiang GL
Diabetes Res Clin Pract; 2014 Oct; 106(1):19-26. PubMed ID: 24837144
[TBL] [Abstract][Full Text] [Related]
7. Metformin use and prostate cancer risk: A meta-analysis of cohort studies.
Feng Z; Zhou X; Liu N; Wang J; Chen X; Xu X
Medicine (Baltimore); 2019 Mar; 98(12):e14955. PubMed ID: 30896668
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.
Soranna D; Scotti L; Zambon A; Bosetti C; Grassi G; Catapano A; La Vecchia C; Mancia G; Corrao G
Oncologist; 2012; 17(6):813-22. PubMed ID: 22643536
[TBL] [Abstract][Full Text] [Related]
9. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Zhang H; Gao C; Fang L; Zhao HC; Yao SK
Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049
[TBL] [Abstract][Full Text] [Related]
10. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.
Wu Y; Liu HB; Shi XF; Song Y
PLoS One; 2014; 9(6):e99577. PubMed ID: 24924771
[TBL] [Abstract][Full Text] [Related]
11. Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis.
Meng F; Song L; Wang W
J Diabetes Res; 2017; 2017():5063239. PubMed ID: 28271076
[No Abstract] [Full Text] [Related]
12. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis.
Zhang ZJ; Bi Y; Li S; Zhang Q; Zhao G; Guo Y; Song Q
Am J Epidemiol; 2014 Jul; 180(1):11-4. PubMed ID: 24920786
[TBL] [Abstract][Full Text] [Related]
13. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.
Noto H; Goto A; Tsujimoto T; Noda M
PLoS One; 2012; 7(3):e33411. PubMed ID: 22448244
[TBL] [Abstract][Full Text] [Related]
15. Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis.
Nie Z; Zhu H; Gu M
Pharm Biol; 2016 Nov; 54(11):2636-2642. PubMed ID: 27159666
[TBL] [Abstract][Full Text] [Related]
16. Association of metformin use and cancer incidence: a systematic review and meta-analysis.
O'Connor L; Bailey-Whyte M; Bhattacharya M; Butera G; Hardell KNL; Seidenberg AB; Castle PE; Loomans-Kropp HA
J Natl Cancer Inst; 2024 Apr; 116(4):518-529. PubMed ID: 38291943
[TBL] [Abstract][Full Text] [Related]
17. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of metformin alone or as an add-on therapy to insulin in pregnancy with GDM or T2DM: A systematic review and meta-analysis of 21 randomized controlled trials.
He K; Guo Q; Ge J; Li J; Li C; Jing Z
J Clin Pharm Ther; 2022 Feb; 47(2):168-177. PubMed ID: 34363237
[TBL] [Abstract][Full Text] [Related]
19. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes.
Smiechowski BB; Azoulay L; Yin H; Pollak MN; Suissa S
Diabetes Care; 2013 Jan; 36(1):124-9. PubMed ID: 22923670
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
